.svg)
Alameda, Calif. – October 30, 2024 – Alveo Technologies, Inc. (Alveo), a leader in decentralized molecular diagnostics with its proprietary IntelliSense™ platform, today announced that it has appointed Chris Cowen as Alveo’s first chief commercial officer. As Alveo prepares to launch its first product in the animal health space and expand beyond human health, Chris will ensure Alveo has the commercial rigor required to distribute products globally.
Chris has over 25 years of regional and global sales, marketing and customer support leadership experience in the biotechnology and life sciences industry. His proven track record of launching numerous new molecular technologies and products across broad markets applicable to Alveo’s platform, include human and animal health diagnostics, agriculture, research and forensics.
“There’s a tremendous need across multiple industries for rapid, accurate test results at the point of need,” said Shaun Holt, CEO at Alveo. “Alveo is at a very exciting and important inflection point as we prepare to ship our first animal health product, and Chris’ expertise will be critical to our success as we transition into a fast-growing, global, commercial-stage company.”
Alveo’s proprietary molecular diagnostic platform can detect up to eight different pathogens from a single sample, returning precise results in 30-45 minutes. Additionally, Alveo's secure Alveo Vista™ portal instantly uploads geotagged results to the cloud, giving public health authorities and other stakeholders real-time insights into the spread of pathogens, empowering rapid containment measures.
“Alveo’s platform has the potential to completely transform how we detect and respond to pathogens, and I look forward to leveraging my experience to support the company’s growth and expansion,” said Chris Cowen, CCO at Alveo. “We have a unique opportunity to decentralize what has traditionally been complex laboratory-based testing with our simple to use, fast and highly sensitive palm-sized molecular testing platform. Alveo enables users to get accurate results quickly at the point of need, allowing them to take fast action based on quality information.”
Alveo is developing tests both internally and with global partners across a wide range of use cases, including infectious diseases for both livestock and companion animals, production crops, food safety and human health diagnostic applications. Alveo’s first animal health diagnostic — a multiplexed test that can detect multiple strains of avian influenza in poultry, including H5N1 — will begin shipping this quarter.
About Alveo Technologies
Alveo Technologies is the first company to make molecular detection and diagnostics universally accessible – on the farm, in the field, in the clinic, or in the manufacturing plant – helping prevent or significantly limit the destructive impact of viruses, fungi, bacteria, and other pathogens by detecting earlier at the Point of Need™. Alveo’s rugged and portable, multiplex-capable diagnostic platform employs IntelliSense, its patented method of direct electrical sensing of nucleic acid amplification to provide affordable, rapid, and accurate results. By enabling early pathogen detection, Alveo helps manage global health, food security, and supply chain resiliency by providing actionable insights at lightspeed. Know Sooner, Act Faster™ with Alveo. For more,visit: https://www.alveotechnologies.com/
Media Contact
Jeff Miller
Jeff@marketstreetgrp.com
541-207-6413
